Genentech disputes new Avastin research data

By BERNADETTE TANSEY, 
Published  2008-11-19 01:14:03
CREDIBLE

80

CredRank

8 credits.

2 discredits.

Genentech's blockbuster cancer drug Avastin is linked to a significantly increased risk of blood clots in the veins, said a team of university researchers whose conclusions were quickly challenged by the big biotechnology company. The risk of the worrisome... Email this Article Add to del.icio.us Add to digg Add to Facebook
Read Full Story »

What Do You Think?

If you think this article is credible and
quality content, please credit this article.

Credit Article

If you think this article is biased or factually inaccurate, please discredit this article.

Discredit Article

Note: This article was initialized with a predicted CredRank based on past performance of the author and source.

More Business Articles

» The Globe And Mail - Obama urges swift action on economy
» The Irish Times - Ryanair, EasyJet complain over Alitalia aid
» Seattle Times - Sarkozy, Merkel, Blair call for new capitalism
» The Globe And Mail - Nova Chemicals to cut 400 jobs
» The Globe And Mail - Kuwait's Global Investment defaults on debt
» The Independent - Bargain hunters give Peacocks a sales boost
» The Globe And Mail - Suncor says oil production on target

Comments

Leave a Comment

Please log in or register to leave a comment.

Logo_small